Drug Delivery of Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) to Target Brain Tumors

Soheil Mehrdadi ¹ *

Cited by CrossRef: 0

1- Jawad M, Shafique U, Din F, Butt A, Khan S, Khan G, Alamri A, Lahiq A, Alsharif S, Almerai K. Nose to brain delivery of escitalopram-loaded nano-structured lipid carriers thermosensitive gel: Formulation, physiochemical, pharmacokinetic and pharmacodynamics evaluation. Journal of Drug Delivery Science and Technology. 2024;97:105800 [Crossref]

2- Arafat M, Sakkal M, Beiram R, AbuRuz S. Nanomedicines: Emerging Platforms in Smart Chemotherapy Treatment—A Recent Review. Pharmaceuticals. 2024;17(3):315 [Crossref]

3- Abu-Hdaib B, Nsairat H, El-Tanani M, Al-Deeb I, Hasasna N. In vivo evaluation of mebendazole and Ran GTPase inhibition in breast cancer model system . Nanomedicine. 2024;19(12):1087 [Crossref]

4- Wang H, Bo W, Feng X, Zhang J, Li G, Chen Y. Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System. IJN. 2024;Volume 19:5581 [Crossref]

5- Li H, Guan M, Zhang N, Wang Y, Liang T, Wu H, Wang C, Sun T, Liu S. Harnessing nanomedicine for modulating microglial states in the central nervous system disorders: Challenges and opportunities. Biomedicine & Pharmacotherapy. 2024;177:117011 [Crossref]